California Life Sciences’ team of experienced government relations professionals located in Sacramento, Washington, D.C., and throughout California’s regional municipalities, directly engage with policymakers on issues of critical importance to our members and the continued success of California’s life sciences sector.

Latest CLS Policy and Advocacy Updates

Advocacy Uncategorized

White House releases executive order on artificial intelligence

After the White House released an executive order on artificial intelligence, Majority Leader Schumer (D-NY) lead conversations on possible legislative...
Read More
Advocacy Uncategorized

Senate Finance Committee approves bipartisan pharmacy benefit manager (PBM) legislation

The Better Mental Health Care, Lower-Cost Drugs, and Extenders Act would require that patients benefit from rebates under Part D...
Read More
Advocacy Uncategorized

CLS Hosts Congressional Briefing On Restoring Full Tax Expensing for R&D Investments

Today we hosted a Congressional briefing on the urgent need to restore full tax expensing for research and development investments....
Read More
Advocacy Uncategorized

CLS and Biotech Select Committee host roundtable in Los Angeles

This week’s roundtable highlighted the growth of life sciences in the LA region as well as both the potential and...
Read More
Advocacy Uncategorized

CLS at The MedTech Conference

It was an enriching week at the MedTech Conference in Anaheim. CLS was proud to be on the local host...
Read More
Advocacy Uncategorized

CLS joins members, patient advocates, partner trades on the Hill

This week on Capitol Hill, the CLS federal advocacy team worked to build support for fixing R&D tax amortization, the...
Read More

About Our Federal and State Advocacy Teams

California Life Sciences engages on federal policy and regulatory items in accordance with the legislative priorities and recommendations of our membership including direct lobbying in Washington, D.C., position and coalition letters, comments and testimony.

The CLS Federal Legislative Committee (FLC) is the primary interface between our membership and identification of the policy items pertinent to CLS’s missions and objectives. The FLC meets monthly to discuss and develop positions and activities regarding federal legislative and regulatory issues of importance to our membership. The FLC also plays an integral role in the development of CLS’s annual federal policy, education, and advocacy agenda.

Our experienced state government relations team engages on behalf of the life sciences sector in multiple ways through strategic collaborations and direct lobbying in Sacramento to advance innovation, investment and job creation for California’s life sciences ecosystem.

In conjunction with the State Legislative Committee (SLC), we identify and develop position statements on issues of interest to CLS’ membership. This SLC group is composed of government affairs professionals at CLS member organizations.

In addition, we aim to favorably shape the policy environment for California’s life sciences industry by creating and leveraging a world class seamless advocacy, public affairs, and government relations program. The team advances a pro-innovation policy agenda, while ensuring patients have access to the right treatment at the right time.


California Life Sciences’ experienced local government relations team engages on behalf of the life sciences sector in multiple ways to advance the innovation, investment, and job creation for California’s life sciences ecosystem.

Local governmental bodies have an increasingly significant impact on the health and growth of California’s life sciences sector. To ensure our voice is heard, CLS provides representation and ensures ongoing dialogue between the industry and local elected officials and agencies throughout California.

Policy and Advocacy News

California Life Sciences Urges Congress to Support Rare Disease Patients

Oct 12, 2023

California Life Sciences (CLS) is pleased to support the Optimizing Research Progress Hope and New (ORPHAN) Cures Act, introduced by Reps. John Joyce, M.D. (R-PA) and Wiley Nickel (D-NC). The bipartisan..

Read More

CLS statement following CMS announcement first drugs subject to price negotiation process

Aug 29, 2023

August 29, 2023 Today’s announcement by the Centers for Medicare and Medicaid Services is another disappointing step in the administration’s price-setting agenda which will irreversibly harm innovation. While CMS has..

Read More

Contact Us

Sam Chung
Vice President, State Government Relations
[email protected]